Apotex Launches First Generic Nilotinib in US with 180-Day Market Exclusivity
Apotex Corp. announced the launch of nilotinib capsules, the first generic version of Tasigna® in the United States, with 180 days of market exclusivity.
Formosa Pharmaceuticals and Cipla Form Strategic Partnership for APP13007 Commercialization Across 11 Countries
Formosa Pharmaceuticals has granted Cipla Limited exclusive rights to market clobetasol propionate ophthalmic suspension 0.05% (APP13007) across 11 countries in Asia, Africa, and South America.
© Copyright 2025. All Rights Reserved by MedPath